August 23, 2022
Life Sciences
  • Pfizer and BioNTech have submitted their application to the Food and Drug Administration (FDA) for emergency use authorization of their updated COVID19 vaccine booster that specifically targets Omicron subvariants BA.4 and BA.5. If approved, the updated vaccine could be available to the public by early to mid-September. According to the companies, the new booster demonstrated a “strong neutralizing antibody response” against various Omicron variants. (Press release here; Articles here, here, here, and here)